Medpace Holdings Inc. (MEDP) exhibits 41.0% gross margins and 27.9% return on invested capital within Health Care (Biotechnology: Commercial Physical & Biological Resarch), balanced against a 34.0x enterprise multiple and 6.9% implied options volatility.
Sustained 41.0% gross profitability converts into 21.1% operating margin and 27.9% ROIC, outpacing sector cost of capital.
ROIC: 27.9% // GM: 41.0%YoY revenue trajectory of +20.0% paired with 3.60% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +20.0% // FCF YLD: 3.60%Altman Z-Score of 9.13 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 9.13 // F-SCORE: 7/9Trading at 42.0x trailing P/E (35.3x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 42.0x // EV/EBITDA: 34.0xOptions market prices a ±6.9% implied move with a 0.98 put/call ratio around $664.00 max pain.
IMPL MOVE: ±6.9% // P/C: 0.98Elevated industry capital intensity and customer concentration in Biotechnology: Commercial Physical & Biological Resarch require continuous execution to defend 17.8% net margins.
NET MARGIN: 17.8% // D/E: 1.39x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for MEDP & activate live FRED threshold breach alerts.